scholarly journals Real‐world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan

2020 ◽  
Author(s):  
Yu‐Chiao Chiu ◽  
Chia‐Chang Chen ◽  
Chung‐Wang Ko ◽  
Szu‐Chia Liao ◽  
Hong‐Zen Yeh ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Real World ◽  
Bowel Disease ◽  
Medical Center ◽  
Efficacy And Safety ◽  
Inflammatory Bowel ◽  
Central Taiwan

scholarly journals DOP19 Real-world healthcare resource utilisation among patients with inflammatory bowel disease administered vedolizumab for 6 months

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S058-S059
Author(s):  
B Cohen ◽  
H Chang ◽  
J R Jason Rogers ◽  
S Garg ◽  
D Lawrence ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
New York ◽  
Real World ◽  
Bowel Disease ◽  
Healthcare Resource ◽  
Medical Center ◽  
Resource Utilisation ◽  
Healthcare Resource Utilisation ◽  
Inflammatory Bowel

Abstract Background Inflammatory bowel disease (IBD) is associated with high healthcare resource utilisation. Vedolizumab (VDZ) is a gut-selective monoclonal antibody that binds the α4β7 integrin and is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). We investigated real-world healthcare resource utilisation for these patients in the 6 months after initiating VDZ treatment. Methods This retrospective, non-interventional, cohort study examined healthcare resource utilisation for adults with IBD treated with VDZ at Mt Sinai Medical Center (New York, NY) between June 1, 2014, and May 31, 2019. IBD-related healthcare resource utilisation (emergency room [ER] visits, hospitalisations, procedures, corticosteroids) and VDZ treatment patterns (induction, persistence, adherence) were assessed for 6 months after first VDZ infusion. Discontinuation was defined as a ≥90-day gap between infusions or stopping VDZ treatment <6 months after the first infusion. Patients who had ≥90-day gaps were not counted as discontinuing if they experienced clinical benefit that continued beyond the 6-month period. Results 880 patients treated with VDZ were assessed. Mean age was 39.6 years; 51.6% of patients were female. 369 (41.9%) and 504 (57.3%) patients were diagnosed with CD and UC, respectively. 81.4% of patients received 3 VDZ induction doses by Day 98; 69.0% received 4 doses by Day 120. The rates of ER visits, hospitalisations and elective surgical or urgent hospitalisations and procedures among VDZ-treated patients were <1 per 100 pt–months. Steroids (oral or IV) were prescribed to 42.2% of patients during the 6-month period. In the 2 months after their last infusion, 81.6% of patients who received ≥3 VDZ doses were steroid-free. Timing of the last infusion was variable. Overall VDZ persistence was 68.0% (65.0% and 70.2% for CD and UC, respectively; Figure). Most patients (67.2%) had ≥80% of days covered in a 180-day period Conclusion At a tertiary IBD centre, VDZ was associated with low healthcare resource utilisation during the first 6 months of treatment. More than two-thirds of patients persisted with treatment, with most being steroid-free at last follow-up.

Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience

2017 ◽  
Vol 23 (3) ◽  
pp. 404-408 ◽  
Author(s):  
Uri Kopylov ◽  
Yulia Ron ◽  
Irit Avni-Biron ◽  
Benjamin Koslowsky ◽  
Matti Waterman ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Real World ◽  
Bowel Disease ◽  
Efficacy And Safety ◽  
Inflammatory Bowel

Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in a Large Tertiary Medical Center

2016 ◽  
Vol 111 ◽  
pp. S270 ◽  
Author(s):  
Mitchell Wice ◽  
Shannon Oppenheim ◽  
Hannah Miller ◽  
Sharmeel Wasan ◽  
Ansu Noronha ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Medical Center ◽  
Efficacy And Safety ◽  
Inflammatory Bowel

Su1920 - Real-World Evidence Comparison of the Efficacy and Safety of Different Bowel Preparation Agents in Individuals with Inflammatory Bowel Disease

2018 ◽  
Vol 154 (6) ◽  
pp. S-632-S-633
Author(s):  
Naomi Sacks ◽  
Abhishek Sharma ◽  
Philip L. Cyr ◽  
Gerald Bertiger ◽  
David N. Dahdal ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Preparation ◽  
Real World ◽  
Bowel Disease ◽  
Efficacy And Safety ◽  
Real World Evidence ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document